Amgen Epogen 3.9% Price Hike, Volume Discount Plan Hit By Rep. Stark
Executive Summary
Rep. Stark (D-Calif.) is urging the Federal Trade Commission to use Amgen's recent 3.9% price increase for Epogen as a point of departure for looking at the relationship of the product's pricing and profits to Medicare rates for dialysis.
You may also be interested in...
Amgen Epogen
The wholesale acquisition price of recombinant epoetin alfa increases 3.9% as of Feb. 24. This is the first pricing increase since Epogen was launched, the company said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials